tradmap

PTHS Pelthos Therapeutics Inc.

$25.08 +0.52%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Pelthos Therapeutics Inc. (PTHS) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $96 million. Shares last traded at $25.08, 32.8% below their 52-week high. Over the past year the stock is up 17.9%. Net profit margin is -165.2%, below the peer median of 5.3%.

Market Cap
$96M
Shares Out
3.8M
EPS (TTM)
$-40.76
P/E Ratio
P/S Ratio
2.22
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$37.30
52-Week Low
$19.48
Volume
1,466
Avg Vol (3m)
1,292.635

Performance

1W
+2.33%
1M
-12.72%
3M
-3.39%
6M
-4.13%
YTD
-8.83%
1Y
+17.88%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
43.46
SMA (50)
$26.95
SMA (200)
$25.73
Price vs SMA50
-6.93%
Price vs SMA200
-2.53%
ATR (14)
$1.54

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$43M
Net Income
$-72M
Gross Margin
78.6%
Operating Margin
-133.4%
Net Margin
-165.2%
Return on Equity
4767.3%
Return on Assets
-52.1%
Current Ratio
1.98
Debt / Equity
-92.51
Revenue Growth (YoY)

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-14.15 2026-08-13
Q1 2026 $-3.09 2026-05-14
FY 2025 $-23.04 2026-03-19
Q3 2025 $-14.96 2025-11-13
Q2 2026 $-8.56 2026-08-13
Q1 2026 $-3.21 2026-05-14

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

PTHS vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
2.22 / 19.49 med
-89% discount
Net margin vs peers
-165.2% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.